Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pulse Biosciences, Inc. (Nasdaq: PLSE) reported no revenue in Q4 2022 due to the discontinuation of commercial dermatology activities. For the full year, revenue reached $700,000, primarily from earlier in the year. Q4 GAAP expenses decreased to $8.7 million from $16.3 million YoY, while the net loss shrank to $9.2 million from $15.4 million. Total cash reserves increased to $61.1 million as of December 31, 2022, up from $28.6 million in 2021. The company is focused on developing NS PFA delivery devices for atrial fibrillation treatments, with a pre-submission meeting with the FDA planned for 2Q23.